Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jakavi

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

- PMLiVE

AstraZeneca expands personalised drug partnership with Horizon

Companies will research drug targets for targeted cancer treatments

- PMLiVE

The oncology market in Canada

Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture

EU flag

EC fines J&J and Novartis in pay-for-delay case

Says companies delayed entry of generic painkiller

- PMLiVE

Novartis’ Tasigna tops Glivec in long-term trial

Boost ahead of patent expiry for leukaemia drug

Novartis building

Novartis myeloma drug clears phase III trial

Panobinostat on course to be first in new class of treatment for bone marrow cancer

Roche - Basel

Roche signs $1bn-plus cancer deal with Molecular Partners

Partnership could create new type of drug conjugate similar to ADCs

- PMLiVE

Celgene signs $3.3bn cancer deal with OncoMed

Includes lead candidate demcizumab

Novartis building

Novartis sets sights on eliminating leprosy

Throws weight behind meeting WHO's 2020 eradication goal

Novartis building

Scientists finds new drug target for malaria

Novartis and academics identify new class of medicines to treat all stages of infection

National Institute for Health and Care Excellence NICE logo

NICE backs two eye treatments

Novartis’ Lucentis and Alimera’s Iluvien received green light for NHS use

- PMLiVE

Nexavar cleared for thyroid cancer by FDA

Bayer and Onyx win expansion of oncology drug’s use in US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links